Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Big Pharma's March Into Biotech Could Make Big Biologics A Big '09 Theme

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

In 2009, some of the biggest new drugs might not technically be drugs at all. Major biologic products could dominate the upcoming year, largely thanks to big pharma's maturing interest in biotechnology
Advertisement

Related Content

Last Gasp Or New Life? 2009's Novel Products Have Blockbuster Potential
Last Gasp Or New Life? 2009's Novel Products Have Blockbuster Potential
Co-Development Deal Brings Bristol A Novel Interferon, ZymoGenetics Much-Needed Cash
Merck’s Ambitious Plans For Follow-On Biologics
Senate Biosimilars Bill Readied For Take-Off In Next Congress
Safety Data Keeps Momenta/Sandoz’ Generic Lovenox In Play With FDA
Follow-On Biologics Market Unfolding: Big Pharma Signals An Interest
Pfizer Unveils New San Francisco-Based Biotech Center, R&D Leaders
Big Pharma's Leap into Biologics: Bridging both Scientific and Cultural Gaps
Big Pharma's Leap into Biologics: Bridging both Scientific and Cultural Gaps

Topics

Advertisement
UsernamePublicRestriction

Register

PS004056

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel